Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Baxter
Covington
Fish and Richardson
Harvard Business School
QuintilesIMS

Generated: July 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,148,401

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,148,401 protect, and when does it expire?

Patent 8,148,401 protects DAURISMO and is included in one NDA.

This patent has forty-nine patent family members in forty-one countries.

Summary for Patent: 8,148,401
Title:Benzimidazole derivatives
Abstract: The present invention relates to a compound of the Formula I ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3A, R.sup.3B, R.sup.4, R.sup.5, X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
Inventor(s): Munchhof; Michael J. (Salem, CT), Reiter; Lawrence A. (Mystic, CT), La Greca; Susan D. (Old Lyme, CT), Jones; Christopher S. (Gales Ferry, CT), Li; Qifang (Stonington, CT)
Assignee: Pfizer Inc. (New York, NY)
Application Number:12/142,119
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,148,401
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,148,401

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer Inc DAURISMO glasdegib maleate TABLET;ORAL 210656-001 Nov 21, 2018 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Pfizer Inc DAURISMO glasdegib maleate TABLET;ORAL 210656-002 Nov 21, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Federal Trade Commission
Boehringer Ingelheim
Medtronic
US Department of Justice
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.